Camptothecin enhances cell death induced by 177Lu-EDTMP in osteosarcoma cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 8, 2014, Pages 317-322

  Kumar, Chandan ^a   Vats, Kusum ^a   Lohar, Sharad P ^a   Korde, Aruna ^a   Samuel, Grace ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu EDTMP; apoptosis; camptothecin; cellular toxicity; osteosarcoma

Indexed keywords

BETA ACTIN; CAMPTOTHECIN; ETHYLENEDIAMINE TETRAMETHYLENE PHOSPHONIC ACID LU 177; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; RADIOPHARMACEUTICAL AGENT; SYNAPTOPHYSIN; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INCUBATION TIME; ISOTOPE LABELING; MTT ASSAY; NONHUMAN; OSTEOSARCOMA CELL; OSTEOSARCOMA CELL LINE; PAPER CHROMATOGRAPHY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84907259414     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1663     Document Type: Article

References (24)

1. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010;40:89.
2. Ogawa K, Washiyama K. Bone target radiotracers for palliative therapy of bone metastases. Curr Med Chem 2012; 19:3290.
3. Banerjee S, Das T, Chakraborty S, et al. Emergence and present status of Lu-177 in targeted radiotherapy: The Indian scenario Radiochim Acta 2012;100:115.
4. Sciuto R, Festa A, Tofani A, et al. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clin Ter 1998;149:43.
5. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001;357:336.
6. Akerley W, Butera J, Wehbe T, et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 2002;94:1654.
7. Pagliaro LC, Delpassand ES, Williams D, et al. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003;97:2988.
8. Amato RJ, Hernandez-McClain J, Henary H. Bone-targeted therapy: Phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol 2008;6:532.
9. Li QY, Zu YG, Shi RZ, et al. Review camptothecin: Current perspectives. Curr Med Chem 2006;13:2021.
10. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1996;88:3888.
11. Herzog TJ. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist 2002;7:3.
12. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641.
13. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077.
14. Kumar C, Korde A, Kumari KV, et al. Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of Lu-EDTMP and 177Lu-EDTMP. Curr Radiopharm 2013;6:146.
15. Pandey BN, Mishra KP. In vitro studies on radiation induced membrane oxidative damage in apoptotic death of mouse thymocytes. Int J Radiat Biol 2003;1:113.
16. Skoog ML, Ollinger K, Skogh M. Microfluorometry using fluorescein diacetate reflects the integrity of the plasma membrane in UVA-irradiated cultured skin fibroblasts. Photodermatol Photoimmunol Photomed 1997;13:37.
17. Kumar C, Pandey BN, Samuel G, et al. Cellular internalization and mechanism of cytotoxicity of 131I-rituximab in Raji cells. J Environ Pathol Toxicol Oncol 2013;32:91.
18. Cory S, Huang DCS, Adams JM. The Bcl-2 fanily: Role in cell survival and oncogenesis. Oncogene 2003;22:8590.
19. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882.
20. Wagner EF, Nebreda AR. Signal integration by JNK and p-38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537.
21. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p-38 Protein Kinases. Science 2002;298:1911.
22. Zhang C, Zhu H, Yang X, et al. P-53 and p-38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549. J Cancer Res Clin Oncol 2010;136:437.
23. Rudolf E, Kralova V, Rudolf K, et al. The role of p-38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells. Mutat Res 2013;741:27.
24. Lee S, Lee HS, Baek M, et al. MAPK signaling is involved in camptothecin-induced cell death. Mol Cells 2002;14:348.